Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics on June 10 at an average price of $545.83, generating about $5.19 million in proceeds. After the sale, Rothblatt held 40,513 shares, a 19% decrease in direct ownership.
- United Therapeutics recently missed earnings expectations, reporting $5.82 EPS versus the $7.00 consensus and revenue of $781.5 million versus $797.4 million expected. Revenue was down 1.6% year over year, though the company still posted a strong net margin of 40.62%.
- Wall Street sentiment remains positive, with 11 analysts rating the stock a Buy and two a Hold. The average price target is $619.42, above the stock’s recent trading level around $545.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company's stock, valued at approximately $22,113,210.79. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $545.40 on Friday. The firm has a fifty day moving average price of $567.24 and a 200-day moving average price of $521.17. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market cap of $23.15 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the business earned $6.63 EPS. United Therapeutics's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group increased their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Finally, TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $619.42.
Get Our Latest Report on UTHR
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the company. Parallel Advisors LLC grew its position in shares of United Therapeutics by 2.8% in the 1st quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company's stock worth $626,000 after buying an additional 29 shares during the last quarter. NewEdge Advisors LLC boosted its stake in United Therapeutics by 24.7% in the 1st quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company's stock worth $1,283,000 after purchasing an additional 428 shares in the last quarter. Janus Henderson Group PLC boosted its stake in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Bull Harbor Capital LLC acquired a new stake in United Therapeutics in the 1st quarter worth approximately $494,000. Finally, Strategic Investment Advisors MI boosted its stake in United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company's stock worth $5,782,000 after purchasing an additional 1,662 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
